ArticlePloS one2020

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.

Thomas T DeLeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.